Brazil's Psychedelic Psychiatric Use: A Scoping Review

Brazil's Unique Position in Psychedelic Research

Brazil holds a distinctive place in the global landscape of psychedelic research, largely due to its cultural and legal embrace of Ayahuasca. This traditional brew, containing the psychoactive compound DMT (N,N-Dimethyltryptamine), is legally protected in Brazil, providing a fertile ground for scientific exploration. A recent scoping review, published on May 30, 2026, highlights Brazil's contributions to the field, focusing on the psychiatric applications of psychedelics.

Mechanisms and Context of Psychedelic Use

The review synthesized findings from 18 studies involving 831 participants, primarily centered on the use of Ayahuasca, Ibogaine, and DMT. Key findings suggest that Ayahuasca and vaporized DMT can produce rapid antidepressant effects, potentially offering new avenues for treating depression. Additionally, Ibogaine shows promise in extending abstinence periods for individuals with substance use disorders (SUDs). These findings are particularly relevant given the challenges faced by contemporary psychiatry in achieving remission for complex psychiatric disorders.

Implications for Policy and Research

Despite promising outcomes, the research is limited by small sample sizes and regional concentration, primarily in Sao Paulo and Rio Grande do Norte. To enhance the validity of these findings, future studies should focus on larger, multicentric trials. Moreover, more rigorous blinding strategies are needed to mitigate expectancy effects and validate the therapeutic potential of these compounds. The integration of traditional practices with scientific research in Brazil offers a unique model that could inform global policy discussions on psychedelic therapy.

Risks and Unknowns

While the therapeutic potential of psychedelics is promising, several risks and unknowns remain. The small scale and regional focus of current studies limit the generalizability of findings. Additionally, the potential for functional unblinding—where participants discern their treatment group due to the noticeable effects of psychedelics—poses a challenge for maintaining methodological rigor. These factors underscore the need for cautious optimism and rigorous scientific inquiry.

Looking Forward

Brazil's integration of traditional Ayahuasca practices with clinical research provides a valuable framework for future studies. As the field of psychedelic research continues to evolve, Brazil's contributions highlight the importance of culturally informed approaches. Future research should aim to expand sample sizes, diversify study locations, and employ robust blinding techniques to further elucidate the therapeutic potential of psychedelics in psychiatry.